{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dasatinib+%28BMS-354825%29",
    "query": {
      "intervention": "Dasatinib (BMS-354825)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 259,
    "total_pages": 26,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dasatinib+%28BMS-354825%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T17:52:01.947Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00452673",
      "title": "Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 52,
      "start_date": "2007-06",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2015-03-24",
      "last_synced_at": "2026-09-29T17:52:01.947Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Chicago, Illinois • New York, New York + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00452673"
    },
    {
      "nct_id": "NCT04626024",
      "title": "Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia",
        "Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission",
        "Chronic Myeloid Leukemia in Remission"
      ],
      "interventions": [
        {
          "name": "Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal",
          "type": "OTHER"
        },
        {
          "name": "Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2020-12-22",
      "completion_date": "2028-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-09-29T17:52:01.947Z",
      "location_count": 4,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04626024"
    },
    {
      "nct_id": "NCT00507767",
      "title": "Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Salivary Gland Squamous Cell Carcinoma",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVA Squamous Cell Carcinoma of the Larynx",
        "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVA Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Verrucous Carcinoma of the Larynx",
        "Stage IVA Verrucous Carcinoma of the Oral Cavity",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVB Squamous Cell Carcinoma of the Larynx",
        "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVB Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Verrucous Carcinoma of the Larynx",
        "Stage IVB Verrucous Carcinoma of the Oral Cavity",
        "Stage IVC Salivary Gland Cancer",
        "Stage IVC Squamous Cell Carcinoma of the Larynx",
        "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVC Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Verrucous Carcinoma of the Larynx",
        "Stage IVC Verrucous Carcinoma of the Oral Cavity",
        "Tongue Cancer"
      ],
      "interventions": [
        {
          "name": "dasatinib",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2007-07",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2014-10-01",
      "last_synced_at": "2026-09-29T17:52:01.947Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00507767"
    },
    {
      "nct_id": "NCT01398046",
      "title": "Effects of Gastric pH on the Pharmacokinetics of Dasatinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib plus Rabeprazole",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib plus Rabeprazole AND Betaine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 10,
      "start_date": "2011-08",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2015-04-28",
      "last_synced_at": "2026-09-29T17:52:01.947Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01398046"
    },
    {
      "nct_id": "NCT00362466",
      "title": "A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2007-04",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2009-11-20",
      "last_synced_at": "2026-09-29T17:52:01.947Z",
      "location_count": 45,
      "location_summary": "Huntsville, Alabama • Little Rock, Arkansas • Alhambra, California + 39 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00362466"
    },
    {
      "nct_id": "NCT01218477",
      "title": "Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "BMS-833923",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2011-01",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-06-17",
      "last_synced_at": "2026-09-29T17:52:01.947Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Baltimore, Maryland • Houston, Texas",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01218477"
    },
    {
      "nct_id": "NCT00123487",
      "title": "Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myeloid Leukemia, Chronic, Accelerated Phase",
        "Leukemia, Lymphoblastic, Acute, Philadelphia-Positive"
      ],
      "interventions": [
        {
          "name": "dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 638,
      "start_date": "2005-06",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-11-03",
      "last_synced_at": "2026-09-29T17:52:01.947Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00123487"
    },
    {
      "nct_id": "NCT02720185",
      "title": "Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2017-05-03",
      "completion_date": "2022-02-08",
      "has_results": true,
      "last_update_posted_date": "2022-06-03",
      "last_synced_at": "2026-09-29T17:52:01.947Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Madison, Wisconsin",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02720185"
    },
    {
      "nct_id": "NCT00608361",
      "title": "Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult B Acute Lymphoblastic Leukemia",
        "Adult Hepatocellular Carcinoma",
        "Adult Nasal Type Extranodal NK/T-Cell Lymphoma",
        "Adult Solid Neoplasm",
        "Adult T Acute Lymphoblastic Leukemia",
        "Advanced Adult Hepatocellular Carcinoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-Cell Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Cutaneous B-Cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Hepatosplenic T-Cell Lymphoma",
        "Intraocular Lymphoma",
        "Localized Non-Resectable Adult Liver Carcinoma",
        "Localized Resectable Adult Liver Carcinoma",
        "Lymphomatous Involvement of Non-Cutaneous Extranodal Site",
        "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Nodal Marginal Zone Lymphoma",
        "Progressive Hairy Cell Leukemia Initial Treatment",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Lymphoma",
        "Recurrent Adult Liver Carcinoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-Cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides and Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Small Intestinal Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Stage II Small Lymphocytic Lymphoma",
        "Stage III Adult Burkitt Lymphoma",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage III Adult Diffuse Mixed Cell Lymphoma",
        "Stage III Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage III Adult Hodgkin Lymphoma",
        "Stage III Adult Immunoblastic Lymphoma",
        "Stage III Adult Lymphoblastic Lymphoma",
        "Stage III Adult T-Cell Leukemia/Lymphoma",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Stage III Grade 1 Follicular Lymphoma",
        "Stage III Grade 2 Follicular Lymphoma",
        "Stage III Grade 3 Follicular Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage III Marginal Zone Lymphoma",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IIIA Mycosis Fungoides and Sezary Syndrome",
        "Stage IIIB Mycosis Fungoides and Sezary Syndrome",
        "Stage IV Adult Burkitt Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Mixed Cell Lymphoma",
        "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage IV Adult Hodgkin Lymphoma",
        "Stage IV Adult Immunoblastic Lymphoma",
        "Stage IV Adult Lymphoblastic Lymphoma",
        "Stage IV Adult T-Cell Leukemia/Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma",
        "Stage IV Marginal Zone Lymphoma",
        "Stage IV Small Lymphocytic Lymphoma",
        "Stage IVA Mycosis Fungoides and Sezary Syndrome",
        "Stage IVB Mycosis Fungoides and Sezary Syndrome",
        "T-Cell Large Granular Lymphocyte Leukemia",
        "Testicular Lymphoma",
        "Untreated Adult Acute Lymphoblastic Leukemia",
        "Untreated Hairy Cell Leukemia",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2008-10",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2015-07-02",
      "last_synced_at": "2026-09-29T17:52:01.947Z",
      "location_count": 23,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 14 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Hays",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00608361"
    },
    {
      "nct_id": "NCT01609816",
      "title": "Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "Multiple",
        "Mycosis Fungoides",
        "Hodgkin's Lymphoma",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2015-02-12",
      "completion_date": "2018-10-09",
      "has_results": false,
      "last_update_posted_date": "2020-03-16",
      "last_synced_at": "2026-09-29T17:52:01.947Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01609816"
    }
  ]
}